NEW YORK (GenomeWeb) – Oxford Gene Technology today said that it received CE-IVD marking for its Cytocell Aquarius P16/3c/7c/17c Probe kit and launched it in Europe.
The kit uses fluorescence in situ hybridization technology for the non-invasive detection of bladder cancer. The urine-based kit detects the three most common aneuploidies associated with bladder cancer, chromosomes 3, 7, and 17, as well as deletions of the 9p21.3 locus, which contains the tumor suppressor gene p16, commonly deleted in bladder cancer, OGT said.
The kit contains ready-to-use reagents and an easy-to-use protocol, the UK-based company said.
OGT last month sold its protein array platform and its next-generation sequencing service business in order to focus on its genomic product business.